Blockchain Registration Transaction Record

LakeShore Biopharma Goes Private in Merger with Oceanpine

LakeShore Biopharma completes going-private merger with Oceanpine Skyline, delisting from OTC markets. Shareholders receive $0.066 per share. The biopharmaceutical company focuses on vaccines and therapeutics using PIKA® technology.

This transaction matters because it privatizes a key developer of vaccines and biologics targeting rabies, hepatitis B, and influenza, potentially accelerating its research and product development away from public market scrutiny. For shareholders, it provides a defined cash exit; for the industry, it highlights the growing trend of biopharma companies seeking private ownership to fund long-term innovation. The PIKA® platform's future could now be advanced with greater strategic flexibility, impacting global health solutions for infectious diseases.